BRCT.F Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioArctic AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 16.04 |
| 52 Week High | SEK 27.66 |
| 52 Week Low | SEK 13.89 |
| Beta | -0.19 |
| 11 Month Change | 1.78% |
| 3 Month Change | -24.34% |
| 1 Year Change | -37.15% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRCT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | -3.0% | 0.9% |
| 1Y | -37.1% | 19.2% | 32.4% |
Return vs Industry: BRCT.F underperformed the US Biotechs industry which returned 18.1% over the past year.
Return vs Market: BRCT.F underperformed the US Market which returned 32.1% over the past year.
Price Volatility
| BRCT.F volatility | |
|---|---|
| BRCT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BRCT.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BRCT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 96 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
| BRCT.F fundamental statistics | |
|---|---|
| Market cap | US$1.40b |
| Earnings (TTM) | -US$8.74m |
| Revenue (TTM) | US$29.63m |
48.2x
P/S Ratio-163.4x
P/E RatioIs BRCT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRCT.F income statement (TTM) | |
|---|---|
| Revenue | SEK 299.35m |
| Cost of Revenue | SEK 82.67m |
| Gross Profit | SEK 216.68m |
| Other Expenses | SEK 304.96m |
| Earnings | -SEK 88.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 72.38% |
| Net Profit Margin | -29.49% |
| Debt/Equity Ratio | 0% |
How did BRCT.F perform over the long term?
See historical performance and comparison